GlassScriptPhysician profile
Indar M Jhamb
NPI 1790876407
$6,020.41
in general payments reported to CMS, 2019-2025
28 companies · $959 in 2025
The $959 reported for 2025 was less than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $415 · 2020: $764 · 2021: $909 · 2022: $954 · 2023: $902 · 2024: $1,117 · 2025: $959.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,944 · Education: $34.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,944.28 |
| Education | $34.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $1,411.42 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $897.82 | 2019-2025 | Airsupra, Fasenra, Breztri |
| Glaxosmithkline, LLC. | $836.69 | 2019-2025 | Arexvy, Nucala, Trelegy Ellipta |
| Pfizer INC. | $537.50 | 2019-2024 | |
| Kaleo, INC. | $327.85 | 2019-2023 | Auvi-Q |
| Regeneron Healthcare Solutions, INC. | $320.34 | 2019-2025 | Dupixent |
| Mylan Specialty L.P. | $261.14 | 2021-2024 | Yupelri |
| Teva Pharmaceuticals USA, INC. | $219.75 | 2020-2023 | Cinqair |
| Galderma Laboratories, L.P. | $141.96 | 2025 | Nemluvio |
| Amgen INC. | $122.34 | 2019-2025 | Tezspire |
| Alk-Abello, INC | $118.13 | 2020-2021 | |
| Lilly USA, LLC | $115.08 | 2025 | Ebglyss |
| Pharming Healthcare, INC. | $99.56 | 2022-2024 | Ruconest |
| Optinose US, INC. | $74.83 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $58.66 | 2025 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $57.74 | 2020-2022 | |
| Blueprint Medicines Corporation | $53.89 | 2023-2025 | Ayvakit |
| Octapharma USA, INC. | $53.47 | 2021 | |
| Hikma Pharmaceuticals USA | $52.35 | 2024 | Ryaltris |
| Sunovion Pharmaceuticals INC. | $37.32 | 2020 | |
| Circassia INC. | $34.98 | 2019 | |
| Dermavant Sciences, INC. | $34.23 | 2024 | Vtama |
| Genentech USA, INC. | $32.81 | 2023-2024 | Xolair |
| Merck Sharp & Dohme LLC | $28.03 | 2021-2023 | |
| Aimmune Therapeutics, INC. | $27.24 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $27.13 | 2025 | Cuvitru |
| Incyte Corporation | $20.72 | 2025 | Opzelura |
| Uswm, LLC | $17.43 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Indar Jhamb listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.